SCM
XFOR icon

Soleus Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Soleus Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-135,033
Closed -$2.35M – 109
2024
Q2 		$2.35M Sell
135,033
-17,631
-12% -$577K 0.21% 74
2024
Q1 		$6.37M Buy
+152,664
New +$4.25M 0.47% 59

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Soleus Capital Management's XFOR Position: Q3 2024 in Review

Soleus Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q3 2024, closing a stake of 135,033 shares — an estimated $2.35M sold.

Soleus Capital Management first reported a position in XFOR in Q1 2024 and held it in 2 quarters. The position peaked at $6.37M in Q1 2024. 97 funds tracked by Wall St. Rank hold XFOR as of Q3 2024.

  • Soleus Capital Management reported no remaining X4 Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Soleus Capital Management sold 135,033 X4 Pharmaceuticals shares in Q3 2024, an estimated $2.35M.
  • Soleus Capital Management first reported a position in X4 Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Soleus Capital Management's X4 Pharmaceuticals position peaked at $6.37M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2024.

Based on Soleus Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.